IVC Filters When to Place One When to Remove One. Objectives. Clinical Problem Venous Thromboembolic Disease (VTED)
|
|
- Lynne Ellis
- 7 years ago
- Views:
Transcription
1 IVC Filters When to Place One When to Remove One Frank C. Lynch, M.D., FSIR Professor of Radiology, Surgery, and Medicine Division Of Interventional Radiology The Penn State Heart &Vascular Institute Milton S. Hershey Medical Center Hershey, PA Objectives Review Venous Thromboembolic Disease (VTED) Discuss indications for IVC filter Placement Discuss role of retrievable IVC filters in the treatment of VTED Clinical Problem Venous Thromboembolic Disease (VTED) DVT begins in Calf Veins If untreated, 25% will extend into the popliteal and femoral veins If untreated, 50% of femoral popliteal DVT will result in Pulmonary embolism VTED is often clinically silent until Pulmonary embolism occurs 70% of patients with symptomatic PE have asymptomatic DVT Only 11% of people with PE have clinical evidence of DVT 1
2 Pulmonary Embolism ~100 cases of PE per 100,000 persons / year in USA 200,000 PE related deaths / year in USA Mortality 11% with acute PE die in one hour 30% if untreated Only 29% of patients with PE are accurately diagnosed $1.5 Billion / year in health care costs Treatment and Prophylaxis of VTED Anticoagulation Low cost Low risk Noninvasive IVC interruption Does not treat DVT Significant Long term complications Poorly studied Clinical Studies Prospective Randomized Trial patients with VTED Recurrent PE rate at 12 days (+DVT / PE) 4.8% without filter, 1.1% with filter (+DVT / +PE) 8.6% without filter, 1.1% with filter No difference in mortality, but.. 2 & 8 year follow up No difference in recurrent PE, mortality, or post thrombotic syndrome Increased rate of recurrent DVT in Filter Group 20.8% vs. 11.6% 1 Decousus H, Leizorovicz, A, et. Al. A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis. N Engl J Med 1998; 338:
3 Long Term Complications of IVC Filtration Historic data based on permanent IVC filters Thrombotic Events Recurrent DVT ~20% IVC Thrombosis % Filter Fracture /Embolization 2 5% IVC Penetration 41% Optional (aka Retrievable) IVC Filters Rationale Offer protection from PE in patients whose contraindication to anticoagulation therapy is temporary. Avoid long term complications of permanent IVC filtration Recurrent DVT Caval Occlusion Filter Fracture / embolization Caval Perforation 3
4 ACCP Recommendations Grading System ACCP Recommendations Grading System Strength of Evidence A B C Consistent Evidence Randomized Controlled Trials Evidence from Randomized Controlled Trails with Limitations Strong Observational Data Evidence from One Critical Outcome or Observational Data Flawed Randomized Controlled Studies Strength of Recommendation 1 Strong 2 Week Applies to most patients / most circumstances Benefits Outweigh Risks New Evidence Unlikely to Change Recommendation Best action may differ based on patient / circumstances Risk / benefits closely matched New Evidence Unlikely to Change Recommendation Applies to most patient / most circumstances Benefits Outweigh Risks Higher Quality Evidence May Change Recommendation Best action may differ based on patient / circumstances Risk / benefits closely matched Higher Quality Evidence May Change Recommendation Applies to most Patients / many circumstances Benefits Outweigh Risks Higher Quality Evidence Likely to Change Recommendation Alternative Therapies may be equally reasonable Uncertain risks/ benefits Higher Quality Evidence Likely to Change Recommendation TREATMENT RECOMMENDATIONS 4
5 Vena Cava Filters for the Initial Treatment of Patients With DVT In patients with acute DVT of the leg, we recommend against the use of an IVC filter in addition to anticoagulants. In patients with acute proximal DVT of the leg and contraindication to anticoagulation, we recommend the use of an IVC filter. Grade 1B: Applies to most patient / most circumstances Benefits Outweigh Risks Higher Quality Evidence May Change Recommendation Vena Cava Filters for the Initial Treatment of Patients With PE In patients with acute PE who are treated with anticoagulants, we recommend against the use of an IVC filter. In patients with acute PE and contraindication to anticoagulation, we recommend the use of an IVC filter Grade 1B: Applies to most patient / most circumstances Benefits Outweigh Risks Higher Quality Evidence May Change Recommendation Vena Cava Filters for the Initial Treatment of Patients With DVT In patients with acute proximal DVT of the leg and an IVC filter inserted as an alternative to anticoagulation, we suggest a conventional course of anticoagulant therapy if their risk of bleeding resolves. Grade 2B Best action may differ based on patient / circumstances Risk / benefits closely matched Higher Quality Evidence May Change Recommendation Remarks: We do not consider that a permanent IVC filter, of itself, is an indication for extended anticoagulation. 5
6 Vena Cava Filters for the Initial Treatment of Patients With PE In patients with acute PE and an IVC filter inserted as an alternative to anticoagulation, we suggest a conventional course of anticoagulant therapy if their risk of bleeding resolves. Grade 2B Best action may differ based on patient / circumstances Risk / benefits closely matched Higher Quality Evidence May Change Recommendation Remarks: We do not consider that a permanent IVC filter, of itself, is an indication for extended anticoagulation. Relative IVC Filter Placement Indications? Large, free floating proximal DVT Iliocaval DVT VTED in the setting of limited cardiopulmonary reserve Massive PE treated by thrombectomy / thrombolysis Chronic PE treated by thromboendarterectomy Thrombolysis for iliocaval DVT PREVENTION RECOMMENDATIONS 6
7 Prevention of VTE in Nonorthopedic Surgical Patients Patients Undergoing General, GI, Urological, Gynecologic, Bariatric, Vascular, Plastic, or Reconstructive Surgery For general and abdominal pelvic surgery patients (any risk level), we suggest that an inferior vena cava (IVC) filter should not be used for primary VTE prevention. Grade 2C Alternative Therapies may be equally reasonable Uncertain risks/ benefits Higher Quality Evidence Likely to Change Recommendation Prevention of VTE in Trauma Patients For major trauma patients, we suggest that an IVC filter should not be used for primary VTE prevention. Grade 2C Alternative Therapies may be equally reasonable Uncertain risks/ benefits Higher Quality Evidence Likely to Change Recommendation Trauma patients with high risk of VTED (EAST 2002 Criteria) Cannot receive anticoagulation because of bleeding risk AND injury leading to immobilization for a prolonged period: 1. Severe closed head trauma 2. Incomplete spinal cord injury with para/quadraplegia 3. Complex pelvic fractures with associated long bone fractures. 4. Multiple long bone fractures Prevention of VTE in Orthopedic Surgery Patients In patients undergoing major orthopedic surgery (any risk level), we suggest against using IVC filter placement for primary prevention over no thromboprophylaxis in patients with an increased bleeding risk or contraindications to both pharmacologic and mechanical thromboprophylaxis. Grade 2C Alternative Therapies may be equally reasonable Uncertain risks/ benefits Higher Quality Evidence Likely to Change Recommendation 7
8 WHEN TO REMOVE AN IVC FILTER Criteria for Discontinuation of Filtration An indication for a permanent IVC filter is not present The risk of clinically significant PE is acceptably low as a result of achieved / sustained appropriate primary treatment or a change in clinical status. No anticipated return to high risk status due to interruption of primary treatment, change in management or change in clinical status. The life expectancy of the patient is long enough that the presumed benefits of discontinuation of filtration can be realized (generally > 6 months) The device can be safely removed or converted 8
9 Discontinuation of Filtration Procedure Outcomes Once the decision is made to discontinue filtration, what is the likelihood of success? 85% success rate stated in literature reviews >98% in published data from HMC Factors that contribute to failed removal include: Thrombosis of the IVC / Filter Filter embedded in the caval wall Tilted filter Perceived Barriers to IVC Filter Removal There are probably no finite implantation times after which IVC filter removal is either unsafe or unlikely to be successful. It is no more difficult to removal an IVC filter the longer that it has been implanted. Depends on the device and patient specific factors. Probably no absolute time limits for any device IVC Filter Removal after Extended Implantation Periods Device Author Days of Implantation (Literature) HMC Experience ALN 1 / ALN Pellerin Angiotech 2 / Option McGuckin days Bard 3 / Recovery Kuo days Bard 3 / G2 Lynch days Bard 3 G2x / Eclipse / 2083 days Cordis 4 / Optease Rimon days Cook 5 / Günther Tulip Lynch days Cook / Celect Lyon days 1 ALN Implants, Chirurgicaux, Ghisonaccia France 2 Angiotech, Vancouver, British Columbia Canada 4 Cordis Corporation, Bridgewater, New Jersey United States 5 Cook Medical, Bloomington, Indiana United States 3 Bard Peripheral Vascular, Tempe Arizona, United States 9
10 Summary IVC filters are an effective second line alternative to anticoagulation therapy for the prevention of PE Long term complications are associated with all devices, the incidence of which increases over time. Patients with Retrievable filters need to be followed Patients with retrievable IVC filters in place without a clear indication for continued IVC filtration should get their devices removed. Almost all retrievable IVC filters can be removed percutaneously References Kaufman JA, Kinney TB, Streiff MB, et al. Guidelines for the use of retrievable and convertible vena cava filters: Report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol 2006; 17: Rogers FB, Cipollee MD, Velmahos G, Rozucki G, Luchetter FA. Practice Management Guidelines for Trauma From the Eastern Association of the Surgery of Trauma (EAST). J Trauma 2002; 53: Crowther MA. Inferior vena cava filters in the management of venous thromboembolism. Amer J of Medicine 2007; Vol 120(10B), S Ray CE, Mitchell E, Zipser S, Kao EY, Brown CF, Moneta GL. Outcomes with retrievable inferior vena cava filters: A multicenter study. J Vasc Interv Radiol 2006; 17: Additional References by Request IVC Filters When to Place One When to Remove One Frank C. Lynch, M.D., FSIR Professor of Radiology, Surgery, and Medicine Division Of Interventional Radiology The Penn State Heart &Vascular Institute Milton S. Hershey Medical Center Hershey, PA 10
11 FACT VS. FICTION Fact vs Fiction There are currently one or more retrievable IVC filter designs that are on recall by the manufacturer. Fiction! 11
12 Filter Recall? Retrievable IVC Filter technology has made it justifiable to place an IVC filter in younger patient populations under the premise that the device will be removed ,000 IVC filters placed ,000 IVC filters placed 2012 est. 259,000 IVC filters to be placed Retrieval rates have historically been between 15% 25% Large number of devices needlessly left in place in young patients for years / decades 189 filters placed After a mean follow up time of 38 months 10 IVC filters retrieved (5.3%) 80 patients with filters in placed screened 13 (16%) fractured Of those 80 patients Mean Age early 50 s 56 (70%) had filters placed either for unknown indications (n=18), trauma (n=17) or electively in high risk surgery patients (n=21). 12
13 Filter Recall? Fact vs Fiction Anticoagulation should be held for the IVC filter removal procedure Fiction! Multiple series with anecdotal reports of safe removals with INR < IVC filter removals, 62 with INR between 2 and /62 (87%) success rate for IVC filter removal No operative bleeding complications 1 Schmelzer TM, Christmas AB, Taylor DA, Heniford BT, Sing RF. Vena cava filter retrieval in therapeutically anticoagulated patients. Am J Surg Dec;196(6):944-6; discussion Fact vs Fiction IVC filters that are embedded in the caval wall, have perforated the IVC or are fractured cannot and should not be removed Fiction! 13
14 14
15 15
16 Relative IVC Filter Placement Indications Examples Iliocaval DVT Large, free floating proximal DVT Massive PE treated by thrombectomy / thrombolysis Chronic PE treated by thromboendarterectomy Thrombolysis for iliocaval DVT VTED in the setting of limited cardiopulmonary reserve Poor compliance with anticoagulation medications High risk of complication of anticoagulation (eg. Ataxia, frequent falls) Thrombectomy and IVC Filter Use in Pediatric Patients With DVT In children with life threatening VTE, we suggest thrombectomy (Grade 2C). In children who have had a thrombectomy, we suggest anticoagulant therapy as per recommendation (2.22)(Grade 2C). In children >10 kg body weight with lower extremity VTE and a contraindication to anticoagulation, we suggest placement of a retrievable IVC fi lter (Grade 2C). In children who receive a filter, we suggest that the filter be removed as soon as possible if thrombosis is not present in the basket of the filter and when contraindication to anticoagulation is resolved (Grade 2C). In children who receive an IVC filter, we recommend appropriate anticoagulation for VTE (see 1.2) as soon as the contraindication to anticoagulation is resolved (Grade 1C). 16
Pulmonary Embolic Disease: Caval Filtration and Other Stuff. Tony P. Smith, M.D. October 2, 2009
Pulmonary Embolic Disease: Caval Filtration and Other Stuff Tony P. Smith, M.D. October 2, 2009 Controversies in Treatment of Acute Pulmonary Embolic Disease Scope of the problem Transcatheter therapy
More informationPosition Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery
Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery Position Statement There is currently insufficient data for the (AOFAS) to recommend for or against routine VTED prophylaxis for
More informationAGENDA. (Nitinol Nickel Titanium Alloy) 7/23/2015
AGENDA What is an IVC filter/what does it do/where implanted? Who are the defendants? What are the injuries Problems? Intake Bard The bad guy story Efficiency/Efficacy Articles/Research FDA Warnings/Advisories
More informationHealth Policy Advisory Committee on Technology Technology Brief
Health Policy Advisory Committee on Technology Technology Brief Inferior vena cava filters in the management of patients considered to be at high-risk of acute venous thromboembolism November 2013 State
More information6/19/2012. Update on Venous Thromboembolism Prophylaxis. Disclosure. Learning Objectives. No conflicts of interest to declare
Update on Venous Thromboembolism Prophylaxis Disclosure No conflicts of interest to declare Learning Objectives After completion of this presentation, participants should be able to: Define venous thromboembolism,
More informationVenous Thromboembolic Treatment Guidelines
Venous Thromboembolic Treatment Guidelines About the NYU Venous Thromboembolic Center (VTEC) The center s mission is to deliver advanced screening, detection, care, and management services for patients
More informationJoseph A. Caprini, MD, MS, FACS, RVT
Joseph A. Caprini, MD, MS, FACS, RVT Louis W. Biegler Chair of Surgery NorthShore University HealthSystem, Evanston, IL Clinical Professor of Surgery University of Chicago Pritzker School of Medicine,
More informationCook Celect and Günther Tulip Vena Cava Filter Patient Guide
Cook Celect and Günther Tulip Vena Cava Filter Patient Guide www.cookmedical.com Filter patient guide Contents Pulmonary embolism 4 5 What is pulmonary embolism? What causes it? What are the symptoms of
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationPublished 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL 60018. AAOS Clinical Practice Guidelines Unit
Volume 4. AAOS Clinical Guideline on Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty Comparison with Other Guidelines Disclaimer This clinical guideline
More informationInvestor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationTrust Guideline for Thromboprophylaxis in Trauma and Orthopaedic Inpatients
A clinical guideline recommended for use In: By: For: Key words: Department of Orthopaedics, NNUHT Medical staff Trauma & Orthopaedic Inpatients Deep vein thrombosis, Thromboprophylaxis, Orthopaedic Surgery
More informationUsing CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital
Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital Jonathan Sykes MD, CMIO Jacalyn Liebowitz RN, MBA,NEA-BCFACHE VP Care Continuum Allegiance Health - Jackson, MI DISCLAIMER:
More informationPaul G. Lee. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume III, 1998-1999. A. Objective
A comparison of six months of anticoagulation with extended anticoagulation for a first episode of venous thromboembolism in patients with thrombophilia Paul G. Lee A. Objective a. To evaluate the risk
More informationInferior Vena Cava filter and removal
Inferior Vena Cava filter and removal What is Inferior Vena Cava Filter Placement and Removal? An inferior vena cava filter placement procedure involves an interventional radiologist (a specialist doctor)
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationVaricose veins and venous thrombosis: The latest treatment options
Varicose veins and venous thrombosis: The latest treatment options DR ROBERT McBANE: I'm Rob McBane from the Vascular Center at Mayo Clinic in Rochester. Today we have the pleasure of talking with my esteemed
More informationTo provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
More informationXARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery
XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery Fast Facts: XARELTO is a novel, once-daily, oral anticoagulant recently approved in the United States for the prevention (prophylaxis)
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationRandomized, double-blind, parallel-group, multicenter, doubledummy
ABOUT RECORD STUDIES FAST FACTS RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE)
More informationAntithrombotic Therapy for VTE Disease
CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationBayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of
More informationAntithrombotic Therapy for VTE Disease
CHEST Supplement ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
More informationNHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationCost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip
Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip Replacement or Total Knee Replacement National Centre
More informationPrior Authorization Guideline
Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204
More informationACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014
ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014 Thromboembolism epidemiology 5 million DVT s 900,000 PE s 290,000 fatalities Heit J. Blood. 2005;106:910. 10 VTE events Since this talk began DVT
More informationDISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION
DISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION Venous thromboembolism is the most common complication after total hip and total knee arthroplasty. In recent times members of the Australian Orthopaedic
More informationEvaluation of inferior vena cava filter retrieval following implementation of dedicated tracking system.
Evaluation of inferior vena cava filter retrieval following implementation of dedicated tracking system. Emily Johnson, Justin Siegal, Robert Crane, Elizabeth Thompson, C Craig Blackmore Disclosures C
More informationCase 6:15-cv-06535 Document 1 Filed 09/08/15 Page 1 of 17 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF NEW YORK
Case 6:15-cv-06535 Document 1 Filed 09/08/15 Page 1 of 17 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF NEW YORK MICHELLE MERCURIO, vs. Plaintiffs, COMPLAINT and DEMAND FOR JURY TRIAL Civil Action No.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPARTICULAR ASPECTS OF ANTI-THROMBOTIC TREATMENT IN HIP ARTHROPLASTY
1 UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PARTICULAR ASPECTS OF ANTI-THROMBOTIC TREATMENT IN HIP ARTHROPLASTY ABSTRACT Ph.D student DR. TRUŞCĂ PAUL TIBERIU SCIENTIFIC COORDONATOR PROF. DR.VALENTIN
More information2. Background This indication of rivaroxaban had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15mg and 20mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: March 2013 1. Purpose of Application The application requested the
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationHot Line Session at European Society of Cardiology (ESC) Congress 2014:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily
More informationPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
More information45 yo fall from ladder
DVT and PE Prophylaxis in Lower Extremity Trauma Daniel T. Altman, MD Associate Professor of Orthopaedic Surgery Drexel University College of Medicine Temple University School of Medicine Allegheny General
More informationChronic Thromboembolic Disease. Chronic Thromboembolic Disease Definition. Diagnosis Prevention Treatment Surgical Nonsurgical
Chronic Thromboembolic Disease Diagnosis Prevention Treatment Surgical Nonsurgical Chronic Thromboembolic Disease Definition Pulmonary Hypertension due to chronic thromboembolism 6 months post acute PE:
More informationNational Guidance and New Protocols
National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 DVT patient pathway Assessment Diagnosis
More informationGruppo di lavoro: Malattie Tromboemboliche
Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationClive Kearon, Susan R. Kahn, Giancarlo Agnelli, Samuel Goldhaber, Gary E. Raskob and Anthony J. Comerota. DOI 10.1378/chest.
Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Clive Kearon, Susan R. Kahn, Giancarlo Agnelli,
More informationConserva)ve Treatment of PE/ DVT
Conserva)ve Treatment of PE/ DVT Amir Kaki, MD FACC FSCAI Asst Prof of Medicine Wayne St SOM Medical Director Cardiac Catheteriza)on Lab Heart Hospital DMC Detroit, MI Incidence Acute pulmonary embolism
More informationService Specification Template Department of Health, updated June 2015
Service Specification Template Department of Health, updated June 2015 Service Specification No. : 2 Service: Commissioner Lead: Provider Lead: Period: Anti-coagulation monitoring Date of Review: 31 st
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationBayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationGuidelines on use of vena cava filters
guidelines Guidelines on use of vena cava filters British Committee for Standards in Haematology: Writing group: T. P. Baglin 1 J. Brush 2 M. Streiff 3 1 Addenbrooke s NHS Trust, Cambridge, 2 Western General
More informationNational Guidance and New Protocols
National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 Autumn dawn Restless geese take flight
More informationAnti-Coagulation Therapies: A Review of Best Practices for Managing Risk
Volume 20 No. 1 Spring 2012 Anti-Coagulation Therapies: A Review of Best Practices for Managing Risk Dear Colleague: This first newsletter of 2012 deals with an important aspect of patient care the monitoring
More informationPulmonary Embolism Treatment Update
UC SF Pulmonary Embolism Treatment Update Jeffrey Tabas, MD Professor UCSF School of Medicine Emergency Department San Francisco General Hospital sf g h Disclosure No Financial Relationships to Disclose
More informationBayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationSeptember 12, 2011. Dear Dr. Corrigan:
September 12, 2011 Janet M. Corrigan, PhD, MBA President and Chief Executive Officer National Quality Forum 601 13th Street, NW Suite 500 North Washington, D.C. 20005 Re: Measure Applications Partnership
More informationGuidelines for diagnosis and management of acute pulmonary embolism
Guidelines for diagnosis and management of acute pulmonary embolism By Dr. Ahmed Zaghloul M.D. Anesthesia & Critical Care 2014 Predisposing factors for VTE Predisposing factor Strong predisposing factors
More informationComponents of CVC Care Bundle. selection
Components of CVC Care Bundle Catheter site selection Site of insertion influences the subsequent risk for CR-BSI and phlebitis The influence of site is related in part to the risk for thrombophlebitis
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationAnticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
More informationNew Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms
More informationInferior Vena Cava Filter Placement and Removal
Scan for mobile link. Inferior Vena Cava Filter Placement and Removal What is Inferior Vena Cava Filter Placement and Removal? In an inferior vena cava filter placement procedure, interventional radiologists
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationComplication Prevention
Nursing Best Practice for the Stroke Patient Complication Prevention Tara Panazzolo, MSN, RN-BC Nursing Performance Improvement Advisor Hackensack University Medical Center New Jersey State Stroke Conference
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Pulmonary Embolism Note: The Canadian Drug Expert Committee (CDEC) previously reviewed rivaroxaban for the treatment of deep vein
More informationDATE: 06 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06
More informationANTICOAGULATION USE FOR THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE
ANTICOAGULATION USE FOR THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE Jamie N. Nadler, M.D. Assistant Professor of Medicine State University of New York at Buffalo Department of medicine Division
More informationHow To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto
News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval
More informationOut with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation
Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants
More informationSpecialty Excellence Award and America s 100 Best Hospitals for Specialty Care 2013-2014 Methodology Contents
Specialty Excellence Award and America s 100 Best Hospitals for Specialty Care 2013-2014 Methodology Contents Introduction... 2 Specialty Excellence Award Determination... 3 America s 100 Best Hospitals
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationVenous thromboembolism: reducing the risk. Quick reference guide. Issue date: January 2010
Issue date: January 2010 Venous thromboembolism: reducing the risk Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital This guideline
More informationInpatient Quality Reporting Program
Venous Thromboembolism 2015 Abstraction Guidance Questions and Answers Moderator: Candace Jackson, RN Inpatient Quality Reporting Support Contract Lead, HSAG Speakers: Denise Krusenoski, MSN, RN, CMSRN,
More informationBayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment
More informationBackgrounder. Current anticoagulant therapies
Backgrounder Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Current anticoagulant therapies Anticoagulant drugs have significantly reduced the risk of thromboembolic events
More informationTo aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.
UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight
More informationEMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention
More informationUHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient
Guidelines for Anticoagulation Initiation and Management Y2014 UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient Topic Page Number MEDICATION FLOW AND PATIENT FLOW... 2 AND 3 PARENTERAL ANTICOAGULANTS...
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationTop 10 Thrombosis and Anticoagulation Highlights from ASH 2014
Top 10 Thrombosis and Anticoagulation Highlights from ASH 2014 Stephan Moll, MD UNC School of Medicine, Chapel Hill, NC 1. New Anticoagulant Factor XI lowering drug NEJM publication Dec 7 th (late- breaking
More informationJohn E. O Toole, Marjorie C. Wang, and Michael G. Kaiser
Hypothermia and Human Spinal Cord Injury: Updated Position Statement and Evidence Based Recommendations from the AANS/CNS Joint Sections on Disorders of the Spine & Peripheral Nerves and Neurotrauma &
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationDabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
More informationDamage Control in Abdominal Trauma
Damage Control in Abdominal Trauma Steven Stylianos, MD Surgeon-in-Chief, Morgan Stanley Children s Hospital Rudolph Schullinger Professor of Surgery, Columbia University College of Physicians & Surgeons
More informationFort Hamilton Hospital Specialty: Cardiology Department of Medicine Delineation of Privileges
NAME Fort Hamilton Hospital Specialty: Cardiology Department of Medicine Delineation of Privileges GENERAL CARDIOLOGY Required Qualifications for General Cardiology Education/Training/Experience Must have
More informationWhat is the appropriate duration of treatment for VTE? Any advances in predicting recurrence?
What is the appropriate duration of treatment for VTE? Any advances in predicting recurrence? Beverley Hunt Thrombosis & Haemostasis, King s College Guy s & St Thomas Trust Medical Director of Lifeblood:
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationNWMIC Medicines FAQ. New oral anticoagulants (NOACs) and management of dental patients - Dabigatran, rivaroxaban and apixaban.
NWMIC Medicines FAQ New oral anticoagulants (NOACs) and management of dental patients - Date prepared: May 2013, updated November 2013 Summary In primary care; Consider liaising with the local hospital
More informationEliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.
Eliquis (apixaban) Policy Number: 5.01.573 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary
More informationTraveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven
Traveller s Thrombosis Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven Case 1: To thromboprophylaxe or not Women, aged 49, BMI 29, Combined Oral Contraceptives. Family history of provoked
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 10 March 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 March 2010 ARIXTRA 1.5 mg/0.3 ml, solution for injection in pre-filled syringe Box of 2 (CIP: 363 500-6) Box of
More informationMedication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationDabigatran & Rivaroxaban Rat Poison in Better Packaging?
& Rat oison in Better ackaging? Declaration have no conflicts of interest to declare Rochelle M Gellatly BSc(harm), AR, harmd linical harmacy Specialist, ardiac Surgery St. aul s Hospital, rovidence Health
More information